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Abstract
Model- informed precision dosing (MIPD) using therapeutic drug/biomarker monitor-
ing offers the opportunity to significantly improve the efficacy and safety of drug 
therapies. Current strategies comprise model- informed dosing tables or are based on 
maximum a posteriori estimates. These approaches, however, lack a quantification 
of uncertainty and/or consider only part of the available patient- specific information. 
We propose three novel approaches for MIPD using Bayesian data assimilation (DA) 
and/or reinforcement learning (RL) to control neutropenia, the major dose- limiting 
side effect in anticancer chemotherapy. These approaches have the potential to sub-
stantially reduce the incidence of life- threatening grade 4 and subtherapeutic grade 0 
neutropenia compared with existing approaches. We further show that RL allows to 
gain further insights by identifying patient factors that drive dose decisions. Due to its 
flexibility, the proposed combined DA- RL approach can easily be extended to inte-
grate multiple end points or patient- reported outcomes, thereby promising important 
benefits for future personalized therapies.
INTRODUCTION
Personalized dosing offers the opportunity to improve safety 
and efficacy of drugs beyond the current practice.1 This is 
particularly crucial for drugs that exhibit narrow therapeutic 
indices relative to the variability between patients. Patient- 
specific dose adaptations during ongoing treatments, how-
ever, are difficult to implement due to the need to integrate 
multiple sources of information, and labels often only give 
simplified guidelines for dose adaptations, like dose reduc-
tions for severe/life- threatening toxicities.2,3
A particularly critical case is cytotoxic anticancer che-
motherapy with neutropenia as major dose- limiting toxicity.4 
Patients with severe neutropenia experience a drastic reduc-
tion of neutrophil granulocytes and are thus highly suscep-
tible to potentially life- threatening infections. Depending 
on the lowest neutrophil concentration (nadir), the different 
grades g  of neutropenia range from no neutropenia (g = 0) 
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to life- threatening (g = 4).5 At the same time, neutropenia 
serves as a surrogate for efficacy (in terms of median [over-
all] survival).6– 8 Neutrophil concentrations can therefore be 
used as a biomarker to guide dosing and therapy management 
of chemotherapeutic agents that cause neutropenia.9– 11
In this paper, we consider paclitaxel- induced neutrope-
nia as an illustrative and therapeutically relevant application. 
Paclitaxel is used as first- line treatment against non- small 
cell lung cancer in platinum- based combination therapy.12 
The standard dosing of paclitaxel is based on the patient’s 
body surface area (BSA). To individualize treatment, a dos-
ing table based on sex, age, BSA, drug exposure, and toxicity 
was developed previously13 and evaluated in a clinical trial 
(hereafter the “CEPAC- TDM study”).14
Model- informed precision dosing (MIPD) describes ap-
proaches for dose individualization that take into account 
prior knowledge on the drug- disease- patient system and 
associated variability (e.g., from a nonlinear mixed effects 
[NLMEs] analysis) as well as patient- specific therapeutic 
drug/biomarker monitoring (TDM) data.15 A popular ap-
proach is based on maximum a posteriori (MAP) estima-
tion,16– 18 which infers the individual model parameters of 
the pharmacokinetic/pharmacodynamic (PK/PD) model. 
MAP- based outcomes are typically evaluated with respect to 
a utility function or a target concentration to determine the 
next dose (MAP- guided dosing).17,19 The definition of a tar-
get concentration or utility function is, however, difficult be-
cause in many therapies rather subtherapeutic or toxic ranges 
are known. For therapeutic ranges, MAP- guided dosing is not 
readily suited,20 because only a (potentially biased) point es-
timate is used, neglecting associated uncertainties.21 A post 
hoc uncertainty quantification for MAP- based predictions 
often relies on a normal approximation located at the MAP 
estimate, which was previously shown to not necessarily 
transform accurately into quantities of interest for nonlinear 
models (e.g., to the nadir concentration21).
Reinforcement learning (RL) has been applied to various 
fields in health care, however, mainly focusing on clinical 
trial design,22,23 and only few studies relate to optimal dos-
ing in a PK/PD context.24,25 In model- based RL, it is learned 
how to act best in an uncertain environment using model sim-
ulations. A key aspect of learning is to make successively 
use of knowledge already acquired, while also exploring yet 
unknown sequences of actions. The result is typically a de-
cision tree (or some functional relationship). In other words, 
the physician’s decision is supported via a precalculated, ex-
tensive, and detailed look- up table without additional compu-
tation during the course of therapy.
Recently, we have shown that Bayesian data assimilation 
(DA) approaches provide informative clinical decision sup-
port, fully exploiting patient- specific information.21 DA al-
lows for individualized uncertainty quantification, which can 
be used in a straightforward way (i) to integrate both safety 
and efficacy aspects into the objective function of finding 
the optimal dose, or (ii) to accurately compute the probabil-
ity of being within/outside the target range. However, opti-
mizing across a whole therapy time frame can be hard and 
potentially too costly for real- time decision support.
In this paper, we demonstrate how DA and RL can be 
very beneficially exploited to develop new approaches to 
MIPD. The first approach, referred to as DA- guided dos-
ing, improves existing online MIPD by integrating model 
uncertainties into the dose selection process. For the sec-
ond approach (RL- guided dosing) we propose the Monte 
Carlo tree search (MCTS) in conjunction with the upper 
confidence bound applied to trees (UCT)26,27 as sophisti-
cated learning strategy. The third approach combines DA 
and RL (DA- RL- guided) to make full use of patient TDM 
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON 
THE TOPIC?
Current strategies to model- informed precision dos-
ing (MIPD) are either static model- informed dos-
ing tables or maximum a posteriori estimate- based 
approaches.
WHAT QUESTION DID THIS STUDY 
ADDRESS?
How could Bayesian data assimilation (DA) and re-
inforcement learning (RL) methodology be used and 
combined to advance current approaches towards 
MIPD?
WHAT DOES THIS STUDY ADD TO OUR 
KNOWLEDGE?
We propose more comprehensive approaches to 
MIPD, which use RL for complex patient state/dose 
combinations and/or Bayesian DA for individual-
ized uncertainty quantification and propagation to the 
therapeutic outcome. The combination of the two ap-
proaches allows efficient allocation of computational 
resources and brings together the advantages of the 
individual approaches. We compare these novel dos-
ing strategies with traditional approaches to control 
chemotherapy- induced neutropenia.
HOW MIGHT THIS CHANGE DRUG 
DISCOVERY, DEVELOPMENT, AND/OR 
THERAPEUTICS?
Well- informed and efficient MIPD bears the potential 
to bring potentially safe and efficacious drugs with 
narrow therapeutic index and/or high between patient 
variability to the market and improve therapeutic 
management in individual patients under- represented 
in clinical studies.
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data and to provide a flexible, interpretable, and extendable 
framework. We compared the three proposed approaches 
with current dosing strategies in terms of dosing perfor-
mance and their ability to provide insights into the factors 
driving dose selection.
METHODS
We consider a single dose every 3 weeks schedule for 
paclitaxel- based chemotherapy, usually termed a cycle 
c = 1,⋯, C, for a total of 6 cycles (C = 6). We denote the 
decision timepoint for the dose of cycle c by Tc, and assume 
T1 = 0 (therapy start). For dose selection, the physician has 
different sources of information available, such as the pa-
tient’s covariates “cov” (sex, age, etc.), the treatment history 
(drug, dosing regimen, etc.), and TDM data related to PK/PD 
(drug concentrations, response, toxicity, etc.). Despite these 
multiple sources of information, it remains a partial and im-
perfect information problem, as only noisy measurements of 
few quantities of interest at certain timepoints are available. 
MIPD aims to provide decision support by linking prior in-
formation on the drug- patient- disease system with patient- 
specific TDM data.
The standard dosing for 3- weekly paclitaxel, as applied 
in the CEPAC- TDM study arm A, is 200mg∕m2BSAand 
a 20% dose reduction if neutropenia grade 4 (gc = 4) was 
observed.14 The aforementioned dosing table (termed PK- 
guided dosing13) was evaluated in study arm B, see Section 
S3 in Appendix S1. For dose selection at cycle start Tc, we 
chose the patient state:
with s0 = (sex, age;ANC0 ). The covariates sex, age, have 
previously been identified as important predictors of ex-
posure,13 and baseline absolute neutrophil counts ANC0
, as a crucial parameter in the drug- effect model.28,29 We 
included the neutropenia grades of all previous cycles 
g1:c−1 = (g1,⋯, gc−1 ) to account for the observed cumulative 
behavior of neutropenia.29,30
MIPD framework
MIPD builds on prior knowledge from NLME analyses of 
clinical studies.21 The structural and observational models 
are generally given as:
with state vector x = x ( t) (e.g., neutrophil concentra-
tion), parameter values  (e.g., mean transition time), 
and rates of change f(x ;, d ) for given doses d. The ini-
tial conditions x0 are given by the pretreatment levels 
(e.g., ANC0). A statistical model links the observables, 









at timepoints tj to observations (tj, yj)j=1,…,n taking into 
account measurement errors and potential model mis-
specifications, for example:
with j∼iid (0,Σ). In more general terms, 
Yj|Θ= ∼ p ( ⋅ | ;hj () ,Σ) , with j = 1,⋯, n independent. The 
prior distribution for the individual parameters is given by a co-
variate and statistical model:
with TV (cov) denoting the typical values, which generally 
depend on covariates “cov,” and Ω the magnitude of the in-
terindividual variability. We used the term “model” to refer 
to Equations 2– 5, and the term “model state of the patient” to 
refer to a model- based representation of the state of the patient 
(i.e., a distribution of state- parameter pairs (x,  ) or just a single 
[reference] state- parameter pair). In the proposed approaches, 
the model is used to simulate treatment outcomes (in RL called 
“simulated experience”), or to assimilate TDM data and infer 
the model state of the patient, or both. To infer the patient state 
in Equation 1, the grade of neutropenia of the previous cycle 
gc−1 needs to be determined; either directly from the TDM 
data (yc−1 ↦ gc−1 ↦ sc−1) or based on a model simulation of 
the model state of the patient ((x,  ) ↦ cnadir ↦ gc−1 ↦ sc−1). 
Because generally measurements are not taken exactly at the 
time of nadir, the model- predicted nadir may provide an im-
proved state estimate.
We considered three different approaches toward MIPD, 
see Figure 1:
(i) Offline approaches support dose individualization 
based on precalculated model- informed dosing tables 
(MIDTs) or dosing decision trees (RL- guided dosing). 
At the start of therapy, a dose based on the patient’s co-
variates and baseline measurements is recommended. 
During therapy, the observed TDM data are used to de-
termine a path through the table/tree; whereas the treat-
ment is individualized to the patient (based on a priori 
uncertainties), the procedure of dose individualization 
itself does not change (i.e., the tree/table is static). As 
such, it can be communicated to the physician before the 
start of therapy.
(ii) Online approaches determine dose recommendations 
based on a model state of the patient and its simulated 
(1)sc−1 = (sex, age;ANC0, g1,⋯, gc−1 ) ,
(2)dx
dt
(t) = f (x (t) ;, d) , x (0) = x0 ()
(3)h ( t) = h (x (t) , )
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outcome. Bayesian DA or MAP estimation assimilate 
individual TDM data to infer the posterior distribution 
or MAP point- estimate as model state of the patient, re-
spectively. Although online approaches tailor the model 
(more precisely, the parameters) to the patient, clinical 
implementation requires an information technology in-
frastructure and/or easy- to- use software. Whereas this 
might constitute a challenging problem that hinders 
broad application,31successful examples of implementa-
tion already exist.32
(iii) Offline– Online approaches combine the advantages of 
dosing decision trees and an individualized model. The 
individualized model is used in two ways, to infer the 
patient state more reliably than sparsely observed TDM 
data and to individualize the dosing decision tree (using 
individualized uncertainties, rather than population- 
based uncertainties).
Key to all approaches is the so- called reward function R 
(RL terminology), also termed cost or utility function, de-
fined on the set  of patient states:
Ideally, the reward corresponds to the net utility of benefi-
cial and noxious effects in a patient given the current state.33 
For neutrophil- guided dosing, a reward function was suggested 
that maps (MAP- based) nadir concentrations to a continuous 
score19 or penalizes the deviation from a target nadir concentra-
tion (cnadir = 1 ⋅ 109cells∕L)
17; in this study, we used a utility 
(6)R: → ℝ.
F I G U R E  1  Overview of different approaches for model- informed precision dosing (MIPD). The different methods can be categorized 
according to the time when the computational effort to calculate the optimal dose must be made. Offline approaches calculate optimal doses for all 
possible covariates and state combinations prior to any treatment, like in precalculated model- informed dosing tables (MIDT) and reinforcement 
learning (RL). The physician selects the dosing recommendation in the table/tree based on specific patient information (covariates, observations). 
Although the therapeutic drug/biomarker monitoring (TDM) data (measured biomarker) are used to determine the entry in the table/tree, the table/
tree itself is static. Online approaches solve an optimization problem at any decision time point (i.e., when a dose has to be given). They integrate 
patient- specific TDM data using Bayesian data assimilation (DA) or maximum a posteriori (MAP) estimation. Offline- online approaches allocate 
computational resources between offline and online. Precalculated dosing decision- trees are individualized during treatment, based on TDM data
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function but also provide a comparison of the results with 
the suggested target concentration, see also Section S8.5 in 
Appendix S1 and Figure S8. The individualized uncertainties 
quantified via DA allow to consider the probability of being 
within/outside the target range in the reward function,21 which 
is more closely related to clinical reality. For the patient state of 
Equation 1 used in RL, we also designed the reward function 
to account for efficacy and toxicity. We chose to penalize the 
short- term goal (avoiding life- threatening grade 4) more than 
the long- term goal (increased median [overall] survival) asso-
ciated with neutropenia grades 1– 48:
RL- guided dosing
RL problems can be formalized as Markov decision processes, 
modeling sequential decision making under uncertainty, and 
are closely related to stochastic optimal control.34 In RL, the 
goal of a so- called agent (here, the virtual physician) is to 
learn a policy (strategy) of how to act (dose) best with respect 
to optimizing a specific expected long- term return (response), 
given an uncertain and delayed feedback environment (virtual 
patient),35– 37 see Figure 2. An introduction to RL in the con-
text of MIPD in descriptive text can be found in ref. 38.
A Markov decision process comprises a sequence includ-
ing states Sc, actions Dc and rewards Rc with the subscript c 
referring to time (e.g., treatment cycle). If there is a natural 
notion of a final time c = C (e.g., therapy of 6 cycles), the se-
quence is called an episode. Every episode corresponds to a 
path in the tree of possibilities (Figure 2). Due to unexplained 
variability between patients (and occasions), transitions be-
tween states are characterized by transition probabilities 
ℙ [Sc+1 = sc+1 |Sc = sc, Dc+1 = dc+1 ]. The reward is defined 
via the reward function (i.e., Rc = R (Sc )), whereas a so- 
called dosing policy  models how to choose the next dose:
Thus, the policy defines the behavior or strategy of the vir-
tual physician (agent). A dosing policy is evaluated based on 
the so- called return Gc at time step c, defined as the weighted 








−1 if gc =0,
−1 if gc =1, 2, 3,
−2 if gc =4. (8) (d |s) = ℙ [Dc+1 = d |Sc = s ] .
(9)





F I G U R E  2  Model- based reinforcement learning (planning). The expected long- term return (action- value function) is estimated based on 
simulated experience (sample approximation Equation 13). For simulating experience, an ensemble of virtual patients is generated, k = 1⋯, K (for 
all covariate [cov] classes 1, l = 1,⋯, L, covariates cov
(k) are sampled within the covariate class and model parameters  ( k ) are sampled from 
the prior distribution). At the start of each cycle C, a dose d ( k )
c
 is chosen according to the current policy k, and the outcome (grade of neutropenia) 
is predicted based on the model ẋ = f (x ; ( k ) , d ( k )
c
) for the sample parameter vector  ( k ) and chosen dose. The updated patient state s ( k )
c+ 1
 is assessed 
using the reward function R. The sequential dose selections (going through the circle C times [left part]) lead to so- called sample episodes; the 
entirety of episodes to a tree structure
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The discount factor  ∈ [0, 1] balances between short- 
term ( → 0) and long- term ( → 1) therapeutic goals (see 
Sections S6 and S8.7 in Appendix S1). Ultimately, the objec-
tive is to maximize the expected long- term return:
given the current state Sc = s and dose Dc+1 = d over the space 
of dosing policies . The function q is called the action- value 
function.36 Learning an optimal policy involves maximizing 
the expected long- term return q, which in turn depends on 
the current estimate of . Therefore, RL approaches typically 
involve an iterative process of value estimation and policy 
improvement.36
Model- based RL methods that rely on sampling (sample- 
based planning) estimate the expected value in Equation 10 
via a sample approximation. To simplify the calculations, we 
have discretized “age” and ANC0 into covariate classes l, 
l = 1,⋯, L. For each class l, consider the sample (also 
called ensemble):
with cov( k ) sampled within l according to the covariate 









 and initial states according 
to Equation 2. Then, for each k = 1,⋯, K with K large, a sam-
ple episode:
using policy k is determined and:
computed. Here, Nk (s, d ) denotes the number of times that dose 
d was chosen in patient state s among the first k episodes, and 





+ r ( k )
c+2
+⋯. Ideally, Nk (s, d ) should be large for 
each state- dose combination to guarantee a good approximation 
of the expected return (law of large numbers). This, however, 
is infeasible for most applications (curse of dimensionality). 
Thus, one is confronted with the trade- off between exploitation 
(choosing the doses that are known to give a high return) and 
exploration (trying new doses that potentially lead to an even 
higher return). In RL, methods have been developed to cope 
with this trade- off; we used MCTS in conjunction with UCT as 
policy in the iterative training process:26,27,40– 42
with UCTk defined based on the current sample estimate 
qk (sc, d):
It successively expands the search tree (Figure 2) by fo-
cusing on promising doses (exploitation, large qk (sc, d)), 
while also encouraging exploration of doses that have not 
yet been tested exhaustively (small Nk (sc, d )relative to the 











 to state sc). 
The parameter cbalances exploration versus exploitation; 
it depends on the range of possible values of the return and 
current state of the therapy (cycle c), see Equation S10 in 
Appendix S1. Finally, we define ̂UCT = Kas estimate of the 
optimal dosing policy in the training setting (learning with 
virtual patients), and q̂UCT = qKas an estimate of the asso-
ciated expected long- term return. In a clinical TDM setting 
(RL- guided dosing), we finally use  ∗ = arg max q̂UCT, i.e., 
c = 0 (no exploration) in Equation 15. See Section S6.1 in 
Appendix S1 for details.
DA- guided dosing
Sequential DA approaches have been introduced as more 
informative alternatives to MAP- based predictions of the 
therapy outcome, because they provide unbiased predictions 
of the therapy outcome and a comprehensive uncertainty 
quantification at the level of the parameters and quantities 
of interest (e.g., neutropenia grades).21 The article by Maier 
et al.,21 provides a more thorough introduction to DA in the 
context of pharmacometrics, including the interpretation of 
domain- specific terminology. The individualized uncertainty 
in the model state of the patient is inferred and propagated 
to the predicted therapy time course, allowing to predict the 
probability of possible outcomes. For this, the uncertainty in 
the individual model parameters is sequentially updated via 
Bayes’ formula, that is:
where y1:c = (y1,…, yc )T denotes the TDM data up to and 
including cycle c, and yc = (yc1,…, ycnc )
T the measurements 
taken in cycle c. Because the posterior distribution p( |y1:c )
generally cannot be determined analytically, DA approaches 
approximate it by an ensemble of so- called particles (a sample 
approximation):
(10)q (s, d) : = 
[
Gc|Sc = s, Dc+1 = d
]
,
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In our context, a particle represents a potential model 
state of the patient (for the specific patient cov) with a 
weighting factor  w ( m )
c
  characterizing how probable the 
state is (given prior knowledge and TDM data up to C). 
As more TDM data is gathered, the Bayesian updates re-
duce the uncertainty in the model parameters and conse-
quently in the therapeutic outcome, see Figure 3 (DA part, 
reduced width of credible intervals/prediction intervals) 
and Section S5 in Appendix S1. Because subtherapeutic as 
well as toxic ranges (i.e., very low or high drug/biomarker 
concentrations), are described by the tails of the posterior 
distribution, the uncertainties provide crucial additional in-
formation compared to the mode (MAP estimate) for dose 
selection.
We chose the optimal dose to be the dose that minimizes 
the weighted risk of being outside the target range (i.e., the a 















w ( m )
c
1{g((m)c ,d)=4}
F I G U R E  3  The interplay of data assimilation (DA) and reinforcement learning (RL). In the planning phase prior to therapy, the expected long- 
term return q0 : = q̂UCT is estimated in Monte Carlo Tree Search (MCTS) with upper confidence bound applied to trees (UCT) using an ensemble 
of covariates (cov)(k) and parameter values (k): p ( |TV (cov(k)) ,Ω ). The first dose is selected based on q0 : = q̂UCT for the patient specific covariate 
class. The DA algorithm initializes a particle ensemble given the patient’s covariates. The ensemble is propagated forward continuously in time, 
and observed patient therapeutic drug/biomarker monitoring (TDM) data (black crosses) is assimilated when it becomes available. This results in 
updated uncertainty, visible as “cuts” in the credible/prediction intervals. In contrast, the RL state evolves in discrete time steps C according to the 
decision timepoints and only considers selected features/summaries of the model state of the patient (e.g., smoothed posterior expectation of nadir 
concentrations translated into neutropenia grades). At each decision timepoint, the posterior model state of the patient is used to refine the prior 
computed q̂UCT (grey tree) for future reachable states (light purple tree). This individualizes the tree based on individualized uncertainties (1:c)
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with g( ( m )
c
, d) denoting the predicted neutropenia grade by 
forward simulation of the m- th particle for dose d. We penalized 
grade 4 more severely than grade 0, i.e., 4 = 2∕3 and 0 = 1∕3, 
similarly as in Equation 7.
The integration of an ensemble of particles into the op-
timization problem, instead of a point estimate (as in MAP- 
guided dosing), increases the computational effort and 
complexity of the problem.
If time or computing power is limited, approximations 
have to be used (e.g., by solving only for the next cycle dose 
rather than all remaining cycles at the cost of neglecting 
long- term effects). Alternatively, the number of particles 
M could be reduced (we used both approximations in this 
study); see also Section S8.6 in Appendix S1. The DA op-
timization problem is stated in the space of actions (doses), 
whereas RL optimizes in the space of states by estimating the 
expected long- term return as an intermediate step (Equation 
13) thereby promising efficient solutions to the sequential 
 decision making problem under uncertainty.36
DA- RL- guided dosing
The particle- based DA scheme and the model- based RL 
scheme address the problem of personalized dosing from 
different angles. A combined DA- RL approach therefore 
offers several advantages by integrating individualized un-
certainties provided by DA within RL, see Figure 3. First, 
instead of the observed grade (e.g., measured neutrophil 
concentration on a given day, translated into the neutropenia 
grade), we may use the smoothed posterior expectation of 
the quantity of interest (e.g., predicted nadir concentration), 
see Section S7 in Appendix S1. This reduces the impact of 
measurement noise and the dependence on the sampling 
day. Second, for model simulations within the RL scheme, 
we can sample from the posterior p( |y1:c ) represented by 
the ensemble 1:c (i.e., from individualized uncertainties, 
instead of the prior p(θ), i.e., population- based uncertain-
ties). During the course of the treatment, the ensemble of 
potential model states of the patient is continuously updated 
when new patient- specific data are obtained (see Equation 
16). This allows to individualize the expected long- term re-
turn during treatment as new patient data is observed, see 
Figure 3 (i.e., the dosing decision tree in RL is updated prior 
to the next dosing decision).
Because the refinement as well as the DA part has to 
run in real- time (online), it has to be performed efficiently. 
We do not need to take all possible state combinations 
into account, but only those that are still relevant for the 
remaining part of the therapy. This reduces the computa-
tional effort, in particular for later cycles. The proposed 
DA- RL approach results in a sequence of estimated opti-
mal dosing policies ̂1, ̂1:2,⋯ with ̂1:c denoting the esti-
mated optimal dosing policy based on TDM data y1:c (i.e., 
based on 1:c). In addition, we do not need to estimate the 
individualized action- value function from scratch, but can 
exploit q0 : = q̂UCT as a prior determined by the RL scheme 
prior to any TDM data (see paragraph following Equation 
15). In predictor + UCT (PUCT27,43), the exploitation ver-
sus exploration parameter c in Equation 15 is modified 
to prioritize doses with high a priori expected long- term 
return:
F I G U R E  4  Pseudo code of DA- RL- guided dosing. At therapy start a particle ensemble 0 for the sequential data assimilation (DA) approach 
is sampled from the prior parameter distribution given the patient’s covariates. Then for the initial state s0 (pretreatment) the first dose is selected 
according to the prior expected long- term return q0 : = q̂UCT calculated beforehand in the prior planning phase (Monte Carlo Tree Search [MCTS] 
with upper confidence bound applied to trees [UCT]). The selected dose is given to the patient and patient- specific therapeutic drug/biomarker 
monitoring (TDM) data yc is collected within cycle c. The TDM data is assimilated via a sequential DA approach (particle filter and smoother) 
creating a posterior particle ensemble 1:c. For subsequent dose decisions (c = 1,⋯, C). The new patient state is inferred using 1:c (e.g., smoothed 
posterior expectation of the nadir concentration translated into the neutropenia grade of the cycle). Then an MCTS is started from the current 
patient state using 1:c in the model simulations. Within the tree search we use the PUCT algorithm with prioritized exploration based on q̂UCT. 
PUCT, predictor upper confidence bound applied to trees; RL, reinforcement learning
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 based on 1:c as an esti-
mate of the optimal individualized dosing policy in the train-
ing setting (using Equations 14 and 19), and ̂qc
PUCT
= qK as an 
estimate of the associated expected long term return based on 
1:c. For individualized dose recommendations in a clinical 
TDM setting, we again use ∗ = arg max q̂1:c
PUCT







































F I G U R E  5  Comparison of different dosing policies for paclitaxel dosing. Comparison of the 90% confidence intervals (CIs) and median of the 
neutrophil concentration for the test virtual population (N = 1000) using (a) pharmacokinetic (PK)- guided dosing, (b) reinforcement learning (RL)- 
guided dosing, (c) maximum a posteriori (MAP)- guided dosing, (d) data assimilation (DA)- guided dosing, and (e) DA- RL- guided dosing, each 
in comparison to the standard dosing (body surface area [BSA]- based dosing). PK- guided dosing is the only approach that also takes into account 
exposure data (TCdrug≥0.05mol∕L). (f) Comparison of the distributions of model- predicted nadir concentrations (smooth by kernel density estimation) 
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Equation 19; see Figure 3 and 4, and Section S7 in Appendix 
S1).
RESULTS
Novel individualized dosing strategies 
decreased the occurrence of grade 4 and 
grade 0 neutropenia compared with existing 
approaches
We compared our proposed approaches with existing ap-
proaches for MIPD based on simulated TDM data in 
paclitaxel- based chemotherapy. The design was chosen to 
correspond to the CEPAC- TDM study14: neutrophil counts 
at days 0 and 15 of each cycle were simulated for virtual 
patients using a PK/PD model for paclitaxel- induced cumu-
lative neutropenia (Figure S1).29 We focused only on pacli-
taxel dosing; we did not take into account drop- outs, dose 
reductions due to nonhematological toxicities, adherence, 
and comedication. Occurrence of grade 4 neutropenia, there-
fore, differed between our simplified simulation study and 
the clinical study (as might be expected), see Section S8.2 
in Appendix S1. This should be taken into account when 
interpreting the results. To obtain meaningful statistics, all 
analyses were repeated 1000 times with covariates sampled 
from the observed covariate ranges in the CEPAC- TDM 
study. Detailed discussions and further analyses are provided 
in Sections S2 and S8 in Appendix S1. The MATLAB code 
is available under (https://doi.org/10.5281/zenodo.3967011).
Figure 5 shows the predicted neutrophil concentrations— 
median and 90% confidence interval (CI)— over 6 cycles of 3 
weeks each. A successful neutrophil- guided dosing should re-
sult in nadir concentrations within the target range (grades 1– 3, 
between black horizontal lines). In all cycles, PK- guided dos-
ing prevented the nadir concentrations (90% CI) to drop as low 
as for the standard dosing (Figure 5a). However, PK- guided 
dosing also increased the occurrence of grade 0 (Figure 6).
RL- guided dosing controlled the neutrophil concentration 
well across the cycles (Figure 5b) and the distribution of nadir 
concentrations over the whole population was increasingly 
concentrated within the target range (Figure 5f). The occur-
rence of grade 0 and 4 neutropenia was substantially reduced 
compared to standard and PK- guided dosing (Figure 6).
For MAP- guided dosing, the occurrence of grade 4 neu-
tropenia increased over the cycles (Figure  6), showing the 
typical cumulative trend of neutropenia,29 despite inclusion of 
TDM data. In contrast, DA steadily guided nadir concentra-
tions into the target range (Figure 5d,f), thereby substantially 
decreasing the variance (i.e., the variability in outcome). The 
occurrence of grade 0 and 4 was reduced considerably in later 
cycles (Figure 6), suggesting that individualized uncertainty 
quantification played a crucial role in reducing the variability 
in outcome.
Integrating individualized uncertainties and consid-
ering the model state of the patient in the RL approach 
(DA- RL- guided dosing) also moved nadir concentrations 
into the target range and clearly decreased the variance 
(Figure  5b,f). The slight differences between DA and 
DA- RL (Figure  6) might be related to the difference in 
weighting grade 0 and 4 in the respective reward functions 
(Equation 18 vs. Equation 7). For additional comparisons, 
see Figure S22.
In summary, individualized uncertainties as in DA- guided 
and DA- RL- guided dosing seemed to be crucial in bringing 
nadir concentrations into the target range and reducing the 
variability of the outcome, thus achieving the goal of therapy 
F I G U R E  6  Occurrence of grade 0 and grade 4 for the different 
dosing policies. The percentage is based on a test virtual population 
(N = 1000) and six cycles (inferred from the model predicted nadir 
concentration). Additional analyses are provided in the supplement, 
Figure S22. DA, data assimilation; MAP, maximum a posteriori; PK, 
pharmacokinetic; RL, reinforcement learning
F I G U R E  7  Expected long- term return across the dose range for dose selection. (a) across the considered covariate combinations for the dose 
selection in cycle 1. The symbols plotted below the x- axis show the optimal dose for the corresponding covariate class (i.e., the arg max of the 
plotted line). (b) For fixed sex and age class (here, men between 50 and 60 years) with different pretreatment neutrophil values ANC0 and observed 
neutropenia grades in cycle 1 (i.e., g1). The optimal dose for the second cycle depends on the neutropenia grade of the previous cycle and the 
pretreatment neutrophil count ANC0 in (109cells∕L). The grey dashed line shows the maximum and minimum possible return from the first cycle (a) 
and the second cycle (b) onwards, with  = 0.5. The covariate classes were chosen based on the CEPAC- TDM study population: inclusion criteria 
were ANC0 > ⋅1.5 ⋅ 109cells∕L; the typical baseline count for men was ANC0 = 6.48 ⋅ 1.5 ⋅ 109cells∕L (arm B). The median age was 63 years ranging 
from 51 to 74 years (5th and 95th percentile of the population in arm B), see refs. 14,38. ANC, absolute neutrophil count; BSA, body surface area.
   | 251RL AND BAYESIAN DA FOR MIPD IN ONCOLOGY
(a)
(b)
252 |   MAIER Et Al.
individualization. For this specific example, both approaches 
showed comparable results, but DA- RL has the greater po-
tential for long- term optimization in a delayed feedback en-
vironment as well as integrating multiple end points.
Identification of relevant covariates via 
investigating the expected long- term return 
in RL
A key object in RL is the expected long- term return or action- 
value function q (s, d ) (see Equation 10). We demonstrate 
that it contains important information to identify relevant co-
variates to individualize dosing.
Figure 7a shows the estimated action- value function for 
RL- guided dosing stratified for the covariates, sex, age, 
and baseline neutrophil counts ANC0 (covariate classes are 
shown in the legend) for the first cycle dose selection. ANC0 
was found to be by far the most important characteristic for 
the RL- based dose selection at therapy start. Differences in 
age and sex played only minor roles. For comparison, the first 
cycle of dose selection in the PK- guided algorithm is only 
based on sex and age. The steepness of the curves gives an 
idea about the robustness of the dose selection.
For the second dose selection, the grade of neutropenia 
in the first cycle (g1) has the largest impact, whereas larger 
ANC0 led to larger optimal doses (Figure 7b). To illustrate 
the dose selection in RL, we extracted a similar decision tree 
to the one developed by Joerger et al.,13 see Figure S13.
DISCUSSION
We present three promising MIPD approaches using DA 
and/or RL that substantially reduced the number of (virtual) 
patients in life- threatening grade 4 and grade 0, a surrogate 
marker for efficacy of the anticancer treatment.
RL- guided dosing in oncology has been proposed before,25 
however, only considering the mean tumor diameter. Because 
only a marker for efficacy was considered, this led to a one- 
sided dosing scheme and resulted in very high optimal doses. 
The authors therefore introduced action- derived rewards (i.e., 
penalties on high doses). In contrast, neutrophil- guided dosing 
considers toxicity and efficacy (link to median survival) simul-
taneously. Ideally, dosing decisions should also include other 
adverse effects (e.g., peripheral neuropathy), tumor response, or 
long- term outcomes (e.g., overall or progression- free survival), 
and other concomitant medication (anticancer combination 
agents; e.g., carboplatin and supportive medication; e.g., gran-
ulocyte colony stimulating factor and other patient- specific co-
medications). Notably, RL easily extends to multiple adverse/
beneficial effects and comedication, and is especially suited for 
time- delayed feedback environments,23,35 as typical in many 
diseases. Unlike current less complex MIDT, the decision tree 
of RL is not straightforward to navigate or remember, therefore, 
an application in clinics would require the development of easy- 
to- use software or dashboards, as, for example, for infliximab.32
So far, RL approaches in health care are limited to rather 
simple exploration strategies (so- called - greedy approaches) 
with one- time step ahead approximations of the look- up table 
(Q- learning).23 Using MCTS with UCT, we used an RL frame-
work that exploits the possibility to simulate until the end of 
therapy and evaluate the return. Consequently, it requires less 
approximations as temporal difference approaches (e.g., Q- 
learning, used in ref. 25) that avoid computation of the return 
via a decomposition (Bellman equation). Moreover, explora-
tion via UCT allows to systematically sample from the dose 
range (as opposed to an - greedy strategy) and allows to in-
clude additional information (e.g., uncertainties or prior infor-
mation [as in PUCT]). This becomes key when combined with 
direct RL based on real- world patient data, see for example,44,45 
which would allow to compensate for a potential model bias. 
At the end of a patient’s therapy, the observed return can be 
evaluated and used to update the expected return q̂̂. This up-
date would even be possible if the physician did not follow 
the dose recommendation (off- policy learning) and could be 
implemented across clinics, as it could be done locally without 
exchanging patient data. Thus, the presented approach builds a 
basis for continuous learning postapproval, which has the po-
tential to substantially improve patient care, including patient 
subgroups under- represented in clinical studies.
Overall, we have shown that DA and RL techniques can 
be seamlessly integrated and combined with existing NLME 
and data analysis frameworks for a more holistic approach 
to MIPD. Our study demonstrates that incorporation of indi-
vidualized uncertainties (as in DA) is favorable over state- of- 
the- art online algorithms such as MAP- guided dosing. The 
integrated DA- RL framework allows not only to consider 
prior knowledge from clinical studies but also to improve and 
individualize the model and the dosing policy simultaneously 
during the course of treatment by integrating patient- specific 
TDM data. Thus, the combination provides an efficient and 
meaningful alternative to solely DA- guided dosing, as it al-
locates computational resources between online and offline 
and the RL part provides an additional layer of learning to 
the model (in form of the expected long- term return) that can 
be used to gain deeper insights into important covariates for 
the dose selection. Therefore, showing that RL approaches 
can be well interpreted in clinically relevant terms (e.g., high-
lighting the role of ANC0 values).
Well- informed and efficient MIPD bears huge potential in 
drug development as well as in clinical practice as it could: 
(1) increase response rates in clinical studies, (2) facilitate 
recruitment by relaxing exclusion criteria, and (3) enable 
continuous learning postapproval and thus improve treatment 
outcomes in the long term.
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